Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

N Engl J Med

21 November Nov 2018 20 days ago
  • Salvioni A

Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.

Reference

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Salvioni A in appendix. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018 Nov 7. doi: 10.1056/NEJMoa1801174. [Epub ahead of print]

Go to PubMed